With President-elect Donald Trump proposing tariffs as high as 60%- 100% on goods imported from China, Wall Street analysts ...

Firstly, Griffin described diabetes as the leading cause of end-stage renal disease (ESRD), which accounts for approximately 45% of all cases of people with ESRD ... on the use of hybrid closed-loop ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

Tandem Diabetes Care (TNDM) and Insulet (PODD) stocks draw outperform ratings at Bernstein as insulin pump makers prepare for ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

Tandem Diabetes Care shares ticked up after hours today on third-quarter results that topped the consensus forecast.

This impressive performance was largely attributed to the successful launch of the company's Mobi insulin pump system. The Mobi launch has been a significant driver of growth for Tandem ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) in the third quarter, Holdings Channel reports. The fund acquired ...

Tandem Diabetes Care reported a strong second quarter in 2024, outperforming expectations in both sales and EBITDA. This impressive performance was largely attributed to the successful launch of the ...

SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...

Insulin pump therapy, also known as continuous subcutaneous insulin infusion (CSII), is an important and evolving form of insulin delivery, which is mainly used for people with type 1 diabetes.